View ValuationWON TECHLtd 将来の成長Future 基準チェック /46WON TECHLtd利益と収益がそれぞれ年間17.3%と20.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に26.6% 29.1%なると予測されています。主要情報17.3%収益成長率29.11%EPS成長率Medical Equipment 収益成長45.8%収益成長率20.5%将来の株主資本利益率26.65%アナリストカバレッジLow最終更新日01 Jun 2026今後の成長に関する最新情報Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.すべての更新を表示Recent updatesNew Risk • 11hNew minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ₩9,370, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 21% over the past three years.お知らせ • May 14WON TECH Co.,Ltd. announced that it expects to receive KRW 75 billion in fundingWON TECH Co.,Ltd. announced a private placement to issue series 3 bearer-type unsecured private placement convertible bonds for gross proceeds of KRW 75,000,000,000 on May 14, 2026. The transaction includes participation from new investors, Beauty Device 2026 PEF for KRW of 40,000,000,000 and PACM KOSDAQ Venture No. 1 General Private Equity Investment Trust, a fund advised by NH Investment & Securities Co., Ltd for KRW 35,000,000,000. The bonds have zero coupon rate and zero yield to maturity rate. The bonds will mature on May 22, 2031. The bonds will be 100% converted into 9,068,923 common shares at a fixed conversion price of KRW 8,270 per share. The conversion period is from May 22, 2027 to April 22, 2031. The payment date of the transaction is May 22, 2026. The transaction has been approved by the board of directors of the company. The securities are subject to prohibition of conversion, division, and merger for one year from the bond issuance date.Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩8,860, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years.Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.お知らせ • Apr 11WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to stabilize stock price, employee compensation and enhancement of shareholder value. The program will expire on October 10, 2026. As of April 9, 2026, the company had 741,749 treasury stock within the scope of dividend and 3,793 treasury stock within the scope of other acquisition.Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.分析記事 • Mar 29We Think WON TECHLtd's (KOSDAQ:336570) Solid Earnings Are UnderstatedThe stock was sluggish on the back of WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) recent earnings report. Our analysis...お知らせ • Mar 10WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,278 per share.Buy Or Sell Opportunity • Feb 05Now 23% undervaluedOver the last 90 days, the stock has risen 9.4% to ₩8,860. The fair value is estimated to be ₩11,478, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩10,220, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,310 per share.分析記事 • Jan 28Does WON TECHLtd (KOSDAQ:336570) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,250, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,331 per share.Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩88.00 (vs ₩54.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩88.00 (up from ₩54.00 in 3Q 2024). Revenue: ₩33.2b (up 24% from 3Q 2024). Net income: ₩7.89b (up 64% from 3Q 2024). Profit margin: 24% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 20WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares. The program will expire on April 20, 2026.Buy Or Sell Opportunity • Oct 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 29% to ₩8,970. The fair value is estimated to be ₩11,268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.分析記事 • Sep 11Investors Shouldn't Overlook The Favourable Returns On Capital At WON TECHLtd (KOSDAQ:336570)If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...分析記事 • Aug 26WON TECH Co.,Ltd. (KOSDAQ:336570) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares have retraced a considerable 25% in the last month, reversing a fair amount...Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩103 (vs ₩50.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩103 (up from ₩50.00 in 2Q 2024). Revenue: ₩39.8b (up 37% from 2Q 2024). Net income: ₩9.20b (up 108% from 2Q 2024). Profit margin: 23% (up from 15% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Aug 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩10,450, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,007 per share.分析記事 • Aug 12Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?KOSDAQ:A336570 1 Year Share Price vs Fair Value Explore WON TECHLtd's Fair Values from the Community and select yours...Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩13,250. The fair value is estimated to be ₩10,991, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 53% in the next 2 years.Buy Or Sell Opportunity • Jun 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩11,450. The fair value is estimated to be ₩9,329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 42% in the next 2 years.分析記事 • Jun 02WON TECH Co.,Ltd.'s (KOSDAQ:336570) Intrinsic Value Is Potentially 24% Below Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, WON TECHLtd fair value estimate is ₩7,805 WON TECHLtd is...Buy Or Sell Opportunity • May 29Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to ₩9,360. The fair value is estimated to be ₩7,788, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 44% in the next 2 years.Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩135 (vs ₩67.00 in 1Q 2024)First quarter 2025 results: EPS: ₩135 (up from ₩67.00 in 1Q 2024). Revenue: ₩37.4b (up 66% from 1Q 2024). Net income: ₩11.9b (up 101% from 1Q 2024). Profit margin: 32% (up from 26% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.分析記事 • May 09WON TECHLtd (KOSDAQ:336570) Is Reinvesting To Multiply In ValueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...分析記事 • Apr 17WON TECH Co.,Ltd.'s (KOSDAQ:336570) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 24.6x WON TECH Co.,Ltd. ( KOSDAQ:336570 ) may be sending very bearish...Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩7,250, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩8,009 per share.Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.Upcoming Dividend • Mar 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.3%).お知らせ • Mar 08WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea分析記事 • Jan 06Market Participants Recognise WON TECH Co.,Ltd.'s (KOSDAQ:336570) Earnings Pushing Shares 30% HigherThose holding WON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares would be relieved that the share price has rebounded 30% in...Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩5,330, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 43% over the past year.分析記事 • Dec 16Investors Could Be Concerned With WON TECHLtd's (KOSDAQ:336570) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩4,820, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past year.分析記事 • Nov 25Why WON TECHLtd's (KOSDAQ:336570) Shaky Earnings Are Just The Beginning Of Its ProblemsInvestors were disappointed by WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) latest earnings release. We did some analysis, and...分析記事 • Nov 22What You Can Learn From WON TECH Co.,Ltd.'s (KOSDAQ:336570) P/E After Its 26% Share Price CrashWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shareholders that were waiting for something to happen have been dealt a blow with...Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩54.00 (vs ₩101 in 3Q 2023)Third quarter 2024 results: EPS: ₩54.00 (down from ₩101 in 3Q 2023). Revenue: ₩26.9b (up 1.9% from 3Q 2023). Net income: ₩4.81b (down 45% from 3Q 2023). Profit margin: 18% (down from 33% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩4,405, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 66% over the past three years.Price Target Changed • Nov 16Price target decreased by 9.5% to ₩10,633Down from ₩11,756, the current price target is an average from 9 analysts. New target price is 119% above last closing price of ₩4,845. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩318 for next year compared to ₩441 last year.分析記事 • Sep 17Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩6,670, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 177% over the past three years.Major Estimate Revision • Aug 19Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩147.5m to ₩144.8m. EPS estimate also fell from ₩460 per share to ₩413 per share. Net income forecast to grow 65% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩12,167 to ₩11,778. Share price fell 12% to ₩5,730 over the past week.Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩50.00 (vs ₩102 in 2Q 2023)Second quarter 2024 results: EPS: ₩50.00 (down from ₩102 in 2Q 2023). Revenue: ₩29.0b (down 4.9% from 2Q 2023). Net income: ₩4.42b (down 51% from 2Q 2023). Profit margin: 15% (down from 30% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,770, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.分析記事 • Jun 14Here's Why We Think WON TECHLtd (KOSDAQ:336570) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Major Estimate Revision • May 16Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩161.2m to ₩149.8m. EPS estimate also fell from ₩576 per share to ₩514 per share. Net income forecast to grow 17% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩13,429. Share price fell 23% to ₩8,600 over the past week.分析記事 • May 13WON TECHLtd (KOSDAQ:336570) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Buy Or Sell Opportunity • May 13Now 36% undervaluedOver the last 90 days, the stock has risen 2.3% to ₩8,380. The fair value is estimated to be ₩13,177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 178%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.分析記事 • Apr 15WON TECHLtd (KOSDAQ:336570) Could Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Buy Or Sell Opportunity • Apr 05Now 21% undervaluedOver the last 90 days, the stock has risen 9.9% to ₩10,280. The fair value is estimated to be ₩12,994, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 179%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩9,720, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 365% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩13,055 per share.分析記事 • Mar 25Impressive Earnings May Not Tell The Whole Story For WON TECHLtd (KOSDAQ:336570)WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) robust earnings report didn't manage to move the market for its stock. Our...Reported Earnings • Mar 21Full year 2023 earnings released: EPS: ₩441 (vs ₩158 in FY 2022)Full year 2023 results: EPS: ₩441 (up from ₩158 in FY 2022). Revenue: ₩115.6b (up 42% from FY 2022). Net income: ₩38.8b (up 190% from FY 2022). Profit margin: 34% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea.Buy Or Sell Opportunity • Mar 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩7,960. The fair value is estimated to be ₩10,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last year. Earnings per share has grown by 32%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 72% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,210, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 338% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,692 per share.Price Target Changed • Feb 15Price target decreased by 8.0% to ₩13,500Down from ₩14,667, the current price target is an average from 6 analysts. New target price is 61% above last closing price of ₩8,400. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₩422 for next year compared to ₩158 last year.New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩10,000, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 393% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩16,716 per share.Price Target Changed • Nov 17Price target decreased by 7.2% to ₩15,083Down from ₩16,250, the current price target is an average from 6 analysts. New target price is 86% above last closing price of ₩8,130. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩441 for next year compared to ₩158 last year.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,750, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 331% over the past three years.Valuation Update With 7 Day Price Move • Sep 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩10,920, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 442% over the past three years.New Risk • Aug 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Price Target Changed • Aug 17Price target increased by 19% to ₩15,500Up from ₩13,000, the current price target is an average from 4 analysts. New target price is 15% above last closing price of ₩13,460. Stock is up 338% over the past year. The company is forecast to post earnings per share of ₩489 for next year compared to ₩158 last year.Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,950, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 548% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,595 per share.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩10,300, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 414% over the past three years.Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₩134 (vs ₩45.03 in 1Q 2022)First quarter 2023 results: EPS: ₩134. Revenue: ₩28.5b (up 82% from 1Q 2022). Net income: ₩11.8b (down 4.0% from 1Q 2022). Profit margin: 41% (down from 78% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩7,770, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years.Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,330, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩5,116 per share.業績と収益の成長予測KOSDAQ:A336570 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028286,50044,85068,00074,000212/31/2027230,92565,87552,50053,333412/31/2026190,83345,80042,00042,00033/31/2026159,66933,72528,73930,352N/A12/31/2025156,83835,22149,81651,138N/A9/30/2025147,25842,96144,21945,326N/A6/30/2025140,90239,88440,78541,810N/A3/31/2025130,10435,10629,71930,925N/A12/31/2024115,25529,11312,96314,927N/A9/30/2024108,65624,4463,1265,496N/A6/30/2024108,15328,3551,6514,833N/A3/31/2024109,64532,95312,55516,087N/A12/31/2023115,62938,83322,78225,956N/A9/30/2023109,69634,51324,78227,236N/A6/30/2023103,72434,74626,20327,767N/A3/31/202392,99720,10220,83021,889N/A12/31/202281,50913,39614,20614,781N/A9/30/202272,94420,72213,65514,473N/A6/30/202265,12914,6188,0568,804N/A3/31/202256,73821,1765,6256,210N/A12/31/202151,06317,0135,5596,091N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A336570の予測収益成長率 (年間17.3% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A336570の収益 ( 17.3% ) KR市場 ( 32.9% ) よりも低い成長が予測されています。高成長収益: A336570の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: A336570の収益 ( 20.5% ) KR市場 ( 16.3% ) よりも速いペースで成長すると予測されています。高い収益成長: A336570の収益 ( 20.5% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A336570の 自己資本利益率 は、3年後には高くなると予測されています ( 26.6 %)成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 20:29終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋WON TECH Co.,Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Ji-Eun KimDB Financial Investment Co. Ltd.Sion KangKorea Investment & Securities Co., Ltd.Hee Ryeong JungKyobo Securities Co., Ltd6 その他のアナリストを表示
Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.
Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.
Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.
Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.
Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.
Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.
New Risk • 11hNew minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 29%After last week's 29% share price gain to ₩9,370, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 21% over the past three years.
お知らせ • May 14WON TECH Co.,Ltd. announced that it expects to receive KRW 75 billion in fundingWON TECH Co.,Ltd. announced a private placement to issue series 3 bearer-type unsecured private placement convertible bonds for gross proceeds of KRW 75,000,000,000 on May 14, 2026. The transaction includes participation from new investors, Beauty Device 2026 PEF for KRW of 40,000,000,000 and PACM KOSDAQ Venture No. 1 General Private Equity Investment Trust, a fund advised by NH Investment & Securities Co., Ltd for KRW 35,000,000,000. The bonds have zero coupon rate and zero yield to maturity rate. The bonds will mature on May 22, 2031. The bonds will be 100% converted into 9,068,923 common shares at a fixed conversion price of KRW 8,270 per share. The conversion period is from May 22, 2027 to April 22, 2031. The payment date of the transaction is May 22, 2026. The transaction has been approved by the board of directors of the company. The securities are subject to prohibition of conversion, division, and merger for one year from the bond issuance date.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩8,860, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years.
Major Estimate Revision • Apr 17Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week.
Price Target Changed • Apr 16Price target decreased by 8.6% to ₩10,600Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year.
お知らせ • Apr 11WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to stabilize stock price, employee compensation and enhancement of shareholder value. The program will expire on October 10, 2026. As of April 9, 2026, the company had 741,749 treasury stock within the scope of dividend and 3,793 treasury stock within the scope of other acquisition.
Major Estimate Revision • Apr 07Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week.
分析記事 • Mar 29We Think WON TECHLtd's (KOSDAQ:336570) Solid Earnings Are UnderstatedThe stock was sluggish on the back of WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) recent earnings report. Our analysis...
お知らせ • Mar 10WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,278 per share.
Buy Or Sell Opportunity • Feb 05Now 23% undervaluedOver the last 90 days, the stock has risen 9.4% to ₩8,860. The fair value is estimated to be ₩11,478, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩10,220, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,310 per share.
分析記事 • Jan 28Does WON TECHLtd (KOSDAQ:336570) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,250, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,331 per share.
Price Target Changed • Nov 20Price target decreased by 11% to ₩11,200Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year.
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩88.00 (vs ₩54.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩88.00 (up from ₩54.00 in 3Q 2024). Revenue: ₩33.2b (up 24% from 3Q 2024). Net income: ₩7.89b (up 64% from 3Q 2024). Profit margin: 24% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 20WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares.WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares. The program will expire on April 20, 2026.
Buy Or Sell Opportunity • Oct 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 29% to ₩8,970. The fair value is estimated to be ₩11,268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.
分析記事 • Sep 11Investors Shouldn't Overlook The Favourable Returns On Capital At WON TECHLtd (KOSDAQ:336570)If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
分析記事 • Aug 26WON TECH Co.,Ltd. (KOSDAQ:336570) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares have retraced a considerable 25% in the last month, reversing a fair amount...
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩103 (vs ₩50.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩103 (up from ₩50.00 in 2Q 2024). Revenue: ₩39.8b (up 37% from 2Q 2024). Net income: ₩9.20b (up 108% from 2Q 2024). Profit margin: 23% (up from 15% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Aug 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩10,450, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,007 per share.
分析記事 • Aug 12Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?KOSDAQ:A336570 1 Year Share Price vs Fair Value Explore WON TECHLtd's Fair Values from the Community and select yours...
Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩13,250. The fair value is estimated to be ₩10,991, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 53% in the next 2 years.
Buy Or Sell Opportunity • Jun 30Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to ₩11,450. The fair value is estimated to be ₩9,329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 42% in the next 2 years.
分析記事 • Jun 02WON TECH Co.,Ltd.'s (KOSDAQ:336570) Intrinsic Value Is Potentially 24% Below Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, WON TECHLtd fair value estimate is ₩7,805 WON TECHLtd is...
Buy Or Sell Opportunity • May 29Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to ₩9,360. The fair value is estimated to be ₩7,788, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 44% in the next 2 years.
Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩135 (vs ₩67.00 in 1Q 2024)First quarter 2025 results: EPS: ₩135 (up from ₩67.00 in 1Q 2024). Revenue: ₩37.4b (up 66% from 1Q 2024). Net income: ₩11.9b (up 101% from 1Q 2024). Profit margin: 32% (up from 26% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Major Estimate Revision • May 14Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week.
分析記事 • May 09WON TECHLtd (KOSDAQ:336570) Is Reinvesting To Multiply In ValueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
分析記事 • Apr 17WON TECH Co.,Ltd.'s (KOSDAQ:336570) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 24.6x WON TECH Co.,Ltd. ( KOSDAQ:336570 ) may be sending very bearish...
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩7,250, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩8,009 per share.
Price Target Changed • Mar 25Price target decreased by 22% to ₩6,167Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year.
Upcoming Dividend • Mar 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.3%).
お知らせ • Mar 08WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea
分析記事 • Jan 06Market Participants Recognise WON TECH Co.,Ltd.'s (KOSDAQ:336570) Earnings Pushing Shares 30% HigherThose holding WON TECH Co.,Ltd. ( KOSDAQ:336570 ) shares would be relieved that the share price has rebounded 30% in...
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩5,330, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 43% over the past year.
分析記事 • Dec 16Investors Could Be Concerned With WON TECHLtd's (KOSDAQ:336570) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩4,820, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past year.
分析記事 • Nov 25Why WON TECHLtd's (KOSDAQ:336570) Shaky Earnings Are Just The Beginning Of Its ProblemsInvestors were disappointed by WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) latest earnings release. We did some analysis, and...
分析記事 • Nov 22What You Can Learn From WON TECH Co.,Ltd.'s (KOSDAQ:336570) P/E After Its 26% Share Price CrashWON TECH Co.,Ltd. ( KOSDAQ:336570 ) shareholders that were waiting for something to happen have been dealt a blow with...
Reported Earnings • Nov 20Third quarter 2024 earnings released: EPS: ₩54.00 (vs ₩101 in 3Q 2023)Third quarter 2024 results: EPS: ₩54.00 (down from ₩101 in 3Q 2023). Revenue: ₩26.9b (up 1.9% from 3Q 2023). Net income: ₩4.81b (down 45% from 3Q 2023). Profit margin: 18% (down from 33% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩4,405, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 66% over the past three years.
Price Target Changed • Nov 16Price target decreased by 9.5% to ₩10,633Down from ₩11,756, the current price target is an average from 9 analysts. New target price is 119% above last closing price of ₩4,845. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩318 for next year compared to ₩441 last year.
分析記事 • Sep 17Is WON TECHLtd (KOSDAQ:336570) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩6,670, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 177% over the past three years.
Major Estimate Revision • Aug 19Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩147.5m to ₩144.8m. EPS estimate also fell from ₩460 per share to ₩413 per share. Net income forecast to grow 65% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩12,167 to ₩11,778. Share price fell 12% to ₩5,730 over the past week.
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩50.00 (vs ₩102 in 2Q 2023)Second quarter 2024 results: EPS: ₩50.00 (down from ₩102 in 2Q 2023). Revenue: ₩29.0b (down 4.9% from 2Q 2023). Net income: ₩4.42b (down 51% from 2Q 2023). Profit margin: 15% (down from 30% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,770, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.
分析記事 • Jun 14Here's Why We Think WON TECHLtd (KOSDAQ:336570) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Major Estimate Revision • May 16Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩161.2m to ₩149.8m. EPS estimate also fell from ₩576 per share to ₩514 per share. Net income forecast to grow 17% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩13,429. Share price fell 23% to ₩8,600 over the past week.
分析記事 • May 13WON TECHLtd (KOSDAQ:336570) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Buy Or Sell Opportunity • May 13Now 36% undervaluedOver the last 90 days, the stock has risen 2.3% to ₩8,380. The fair value is estimated to be ₩13,177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 178%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
分析記事 • Apr 15WON TECHLtd (KOSDAQ:336570) Could Become A Multi-BaggerFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Buy Or Sell Opportunity • Apr 05Now 21% undervaluedOver the last 90 days, the stock has risen 9.9% to ₩10,280. The fair value is estimated to be ₩12,994, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 179%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩9,720, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 365% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩13,055 per share.
分析記事 • Mar 25Impressive Earnings May Not Tell The Whole Story For WON TECHLtd (KOSDAQ:336570)WON TECH Co.,Ltd.'s ( KOSDAQ:336570 ) robust earnings report didn't manage to move the market for its stock. Our...
Reported Earnings • Mar 21Full year 2023 earnings released: EPS: ₩441 (vs ₩158 in FY 2022)Full year 2023 results: EPS: ₩441 (up from ₩158 in FY 2022). Revenue: ₩115.6b (up 42% from FY 2022). Net income: ₩38.8b (up 190% from FY 2022). Profit margin: 34% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea.
Buy Or Sell Opportunity • Mar 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 22% to ₩7,960. The fair value is estimated to be ₩10,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last year. Earnings per share has grown by 32%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 72% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,210, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 338% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,692 per share.
Price Target Changed • Feb 15Price target decreased by 8.0% to ₩13,500Down from ₩14,667, the current price target is an average from 6 analysts. New target price is 61% above last closing price of ₩8,400. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₩422 for next year compared to ₩158 last year.
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩10,000, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 393% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩16,716 per share.
Price Target Changed • Nov 17Price target decreased by 7.2% to ₩15,083Down from ₩16,250, the current price target is an average from 6 analysts. New target price is 86% above last closing price of ₩8,130. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩441 for next year compared to ₩158 last year.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,750, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 331% over the past three years.
Valuation Update With 7 Day Price Move • Sep 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩10,920, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 442% over the past three years.
New Risk • Aug 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Price Target Changed • Aug 17Price target increased by 19% to ₩15,500Up from ₩13,000, the current price target is an average from 4 analysts. New target price is 15% above last closing price of ₩13,460. Stock is up 338% over the past year. The company is forecast to post earnings per share of ₩489 for next year compared to ₩158 last year.
Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,950, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 548% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,595 per share.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩10,300, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 414% over the past three years.
Reported Earnings • May 17First quarter 2023 earnings released: EPS: ₩134 (vs ₩45.03 in 1Q 2022)First quarter 2023 results: EPS: ₩134. Revenue: ₩28.5b (up 82% from 1Q 2022). Net income: ₩11.8b (down 4.0% from 1Q 2022). Profit margin: 41% (down from 78% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • May 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩7,770, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years.
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,330, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩5,116 per share.